arrow
M

Mark Basik

mcgill university
H指数:49
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ATR and PKMYT1 Inhibition Resensitizes a Subset of TNBC Patient-Derived Models to Carboplatin, Inducing Mitotic Catastrophe

ATR和PKMYT1抑制使部分三阴性乳腺癌患者衍生的模型对卡铂重新敏感,并诱导有丝分裂灾难

2026-05-010
PRE
Trends in breast reconstruction for BRCA1/2, PALB2 and other high penetrance germline pathogenic variant carriers undergoing risk reducing mastectomy

BRCA1/2、PALB2及其他高外显率胚系致病性变异携带者接受风险降低性乳房切除术后的乳房再造趋势

2026-04-280
PRE
ASO Visual Abstract: Impact of Ethnicity on the Uptake of Risk-Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in Canada

ASO视觉摘要:种族对加拿大未受影响的BRCA1/2和PALB2携带者接受风险降低性乳房切除术的影响

2026-04-090
PRE
ASO Visual Abstract: Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen

ASO视觉摘要:阿typical Hyperplasia和Lobular Carcinoma In Situ患者中内分泌预防的依从性:低剂量他莫昔芬真实世界使用中的良好趋势

2026-03-130
PRE
Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2− and Triple-Negative Breast Cancer in Canada: The HER2− TRENDS Study

加拿大转移性HR+/HER2−和三阴性乳腺癌的治疗模式与临床结局:HER2− TRENDS研究

2026-03-100
PRE
Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen

阿特ypical Hyperplasia和Lobular Carcinoma In Situ患者中内分泌预防的依从性:低剂量他莫昔芬真实世界应用的良好趋势

2026-02-070
PRE
Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium

遗传性癌症的非侵入性筛查: 一项随机对照试验,用于在CHARM联盟中测试基于游离DNA的早期检测

2026-01-290
OA
Reference-free RNA profiling predicts triple negative breast cancer chemoresistance to neoadjuvant treatment

无参考RNA分析预测三阴性乳腺癌对新辅助治疗的化疗耐药性

2025-12-010
PRE
ASO Visual Abstract: Uptake of Risk Reducing Mastectomy in Older BRCA1/2 and PALB2 Carriers Undergoing Genetic Testing After 60 Years of Age

ASO视觉摘要:60岁后接受基因检测的老年BRCA1/2和PALB2携带者中风险降低性乳房切除术的接受情况

2025-11-100
PRE
Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction The NRG-BR005 Nonrandomized Clinical Trial

乳腺癌瘤床活检用于预测病理完全缓解:NRG-BR005非随机临床试验

2025-05-071
PRE
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis

循环肿瘤DNA在早期三阴性乳腺癌中的作用:一项系统评价和Meta分析

2025-03-120
OA
Impact of Margin Status on Local Recurrence in Patients with Breast Cancer Undergoing Breast-Conserving Surgery After Neoadjuvant Chemotherapy: A Retrospective Multi-Institutional Cohort Study

乳腺癌新辅助化疗后保乳手术患者切缘状态对局部复发的影响: 一项多机构回顾性队列研究

2024-07-050
PRE
Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy

BRCA1/2和PALB2-Associated乳腺癌基因检测的时机: 术前结果披露增加了降低风险的乳房切除术的吸收,减少了不必要的放疗暴露

EJSO
IF2.9
2024-06-015
PRE
Oncologic safety of breast conserving surgery after neoadjuvant chemotherapy in patients with multiple ipsilateral breast cancer: A retrospective multi-institutional cohort study

多发性同侧乳腺癌新辅助化疗后保乳手术的肿瘤学安全性: 一项多机构回顾性队列研究

EJSO
IF2.9
2024-06-012
OAAI